BRPI0720991A8 - Preparação da romidepsina - Google Patents

Preparação da romidepsina

Info

Publication number
BRPI0720991A8
BRPI0720991A8 BRPI0720991A BRPI0720991A BRPI0720991A8 BR PI0720991 A8 BRPI0720991 A8 BR PI0720991A8 BR PI0720991 A BRPI0720991 A BR PI0720991A BR PI0720991 A BRPI0720991 A BR PI0720991A BR PI0720991 A8 BRPI0720991 A8 BR PI0720991A8
Authority
BR
Brazil
Prior art keywords
romidepsin
preparation
adducts
oligomerized
dimerized
Prior art date
Application number
BRPI0720991A
Other languages
English (en)
Inventor
L Verdine Gregory
H Vrolijk Nicholas
Bertel Stephan
Original Assignee
Gloucester Pharmaceuticals Inc
Celgene Corp
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gloucester Pharmaceuticals Inc, Celgene Corp, Sandoz Ag filed Critical Gloucester Pharmaceuticals Inc
Publication of BRPI0720991A2 publication Critical patent/BRPI0720991A2/pt
Publication of BRPI0720991A8 publication Critical patent/BRPI0720991A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PREPARAÇÃO DA ROMIDEPSINA. A presente invenção proporciona um processo aperfeiçoado para a preparação de romidepsina. O processo envolve a produção, purificação ou a armazenagem da romidepsina sob condições que impeçam a formação de adutos indesejáveis. A purificação de romidepsina em pH aparente mais baixo do que aproximadamente 6,0 (por exemplo, entre um pH aparente do 4,0 e 6,0) foi descoberta como impedindo a redução da ligação de dissulfeto da romidepsina e a formação subsequente de adutos dimerizados, oligomerizados, ou polimerizados. A invenção também proporciona composições farmacêuticas de romidepsina monomérica isenta de adutos dimerizados, oligomerizados, ou polimerizados.
BRPI0720991A 2006-12-29 2007-12-28 Preparação da romidepsina BRPI0720991A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88270406P 2006-12-29 2006-12-29
US88269806P 2006-12-29 2006-12-29
US60/882,698 2006-12-29
US60/882,704 2006-12-29
PCT/US2007/089067 WO2008083288A2 (en) 2006-12-29 2007-12-28 Purifiction of romidepsin

Publications (2)

Publication Number Publication Date
BRPI0720991A2 BRPI0720991A2 (pt) 2014-03-18
BRPI0720991A8 true BRPI0720991A8 (pt) 2016-03-15

Family

ID=39493420

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720991A BRPI0720991A8 (pt) 2006-12-29 2007-12-28 Preparação da romidepsina

Country Status (10)

Country Link
US (2) US8691534B2 (pt)
EP (1) EP2102230A2 (pt)
JP (1) JP2010514801A (pt)
CN (2) CN101801994A (pt)
AU (1) AU2007342028B2 (pt)
BR (1) BRPI0720991A8 (pt)
CA (1) CA2674309A1 (pt)
IL (1) IL199547A (pt)
MX (1) MX2009006969A (pt)
WO (1) WO2008083288A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
AU2015202335B2 (en) * 2010-07-12 2017-02-02 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103173390B (zh) * 2013-03-16 2014-09-10 浙江海正药业股份有限公司 一种紫色杆菌菌株及其应用
CN104072589B (zh) * 2013-03-29 2017-09-22 浙江海正药业股份有限公司 抗肿瘤三硫化合物及其制备方法与应用
CN104450837B (zh) * 2013-09-18 2019-01-01 上海医药工业研究院 一种用于生产罗米地辛的方法及发酵培养基
CN104447950A (zh) * 2013-09-18 2015-03-25 上海医药工业研究院 一种罗米地辛的分离纯化方法
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN104262456B (zh) * 2014-09-11 2018-01-09 浙江海正药业股份有限公司 一种罗米地辛的新晶型及其制备方法和用途
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法
US20220049213A1 (en) * 2018-12-24 2022-02-17 Marrone Bio Innovations, Inc. A method for increasing romidepsin production from fermentation broth
CN113549131B (zh) * 2021-08-05 2023-01-17 台州科技职业学院 一种合成罗米地辛二聚合物romipeptide A的制备方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
GB9001318D0 (en) * 1990-01-19 1990-03-21 Fujisawa Pharmaceutical Co Wb968 substances and preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) * 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
WO1999011659A1 (en) 1997-09-02 1999-03-11 Japan Energy Corporation Novel cyclic tetrapeptide derivatives and medicinal use thereof
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
NZ517613A (en) 1999-09-08 2004-01-30 Sloan Kettering Inst Cancer Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US6828302B1 (en) * 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
CN1414971A (zh) * 1999-12-08 2003-04-30 埃克斯西特治疗公司 用作免疫抑制剂的缩肽及其同类物
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
WO2002020817A1 (en) * 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AU2002249938B2 (en) 2001-01-10 2006-12-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1390491B1 (en) 2001-05-02 2008-07-16 The Regents of the University of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
JP4238728B2 (ja) 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
WO2003017763A1 (en) 2001-08-24 2003-03-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003035843A2 (en) 2001-10-25 2003-05-01 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
WO2003053468A1 (en) 2001-12-21 2003-07-03 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US20030134423A1 (en) * 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
JP2005525345A (ja) 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
AU2003211576A1 (en) * 2002-02-20 2003-09-09 Sueharu Horinouchi Histone deacetylase inhibitors and process for producing the same
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
AU2003226014A1 (en) 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040002447A1 (en) 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
US20050065596A1 (en) 2002-07-24 2005-03-24 Xufan Tseng Stents capable of controllably releasing histone deacetylase inhibitors
JP4804004B2 (ja) * 2002-08-20 2011-10-26 アステラス製薬株式会社 関節軟骨細胞外マトリクス分解阻害剤
US7098186B2 (en) * 2002-08-30 2006-08-29 Astellas Pharma Inc Depsipeptide compound
CN1681505A (zh) 2002-09-13 2005-10-12 弗吉尼亚州立大学 用于治疗白血病的а ) N－{ 5－[ 4－( 4－甲基－哌嗪－1－基－甲基)－苯甲酰氨基]－2－甲基苯基}－4－( 3－吡啶基 ) －2－嘧啶－胺和b )组蛋白脱乙酰基酶抑制剂的组合
SE0300098D0 (sv) 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
EP1595952A4 (en) 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
JP4588634B2 (ja) * 2003-04-25 2010-12-01 尚巳 岡田 遺伝子導入効率増強剤および商業的パッケージ
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
SI2238982T1 (sl) 2003-06-27 2013-01-31 Astellas Pharma Inc. Terapevtsko sredstvo za mehkotkivni sarkom
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
SI1663194T1 (sl) 2003-08-26 2010-08-31 Merck Hdac Res Llc Uporaba SAHA za zdravljenje mezotelioma
CN102349927A (zh) 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
MXPA06003066A (es) 2003-09-18 2006-06-20 Combinatorx Inc Combinaciones de farmacos para el tratamiento de neoplasmas.
ES2425083T3 (es) 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
EP1689446B1 (de) 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
WO2005058298A2 (en) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
DE602005015559D1 (de) 2004-02-27 2009-09-03 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
DK1591109T3 (da) 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US20050261174A1 (en) 2004-05-20 2005-11-24 Paul Lewer Insecticidal activity of a cyclic peptide
WO2005117930A2 (en) 2004-06-04 2005-12-15 Sloan-Kettering Institute For Cancer Research Use of thioredoxin measurements for diagnostics and treatments
WO2005123089A2 (en) * 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
ES2368930T3 (es) 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
WO2006055621A2 (en) 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
WO2006060382A2 (en) 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006060429A2 (en) 2004-12-03 2006-06-08 Novartis Ag Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20060229237A1 (en) 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc YW753 PREPARATION STABILIZATION TECHNIQUE
US7439695B2 (en) * 2005-08-19 2008-10-21 Komatsu America Corp. Mechanical braking system for use on a vehicle having an electric propulsion system and automatic retard speed regulation
US7943568B2 (en) * 2005-09-30 2011-05-17 The Ohio State University Research Foundation Antitumor agents
US20090325156A1 (en) * 2005-11-10 2009-12-31 Government of the United States of America, as Represented by Secretary, Dept. of Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2007064691A1 (en) * 2005-12-02 2007-06-07 Nabil Habib Lab Treatment of cancer and other diseases
WO2007084775A2 (en) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
JP2009539862A (ja) * 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
WO2008006535A2 (en) * 2006-07-10 2008-01-17 Medigene Ag Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
AU2007296259A1 (en) 2006-09-15 2008-03-20 Janssen Pharmaceutica Nv Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
CA2670223A1 (en) 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
JP2010516767A (ja) * 2007-01-23 2010-05-20 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンおよびｉ．ａ．ボルテゾミブを含む併用療法
WO2008127659A2 (en) 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
WO2009067543A2 (en) 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009108755A2 (en) 2008-02-27 2009-09-03 Wyeth Pharmaceutical combinations for the treatment of cancer
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
WO2009137649A2 (en) 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8623853B2 (en) 2008-07-23 2014-01-07 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the NUT gene
EP2309854A4 (en) 2008-07-30 2012-06-06 Gloucester Pharmaceuticals Inc ACCELERATED THERAPY:

Also Published As

Publication number Publication date
IL199547A (en) 2017-09-28
JP2010514801A (ja) 2010-05-06
CA2674309A1 (en) 2008-07-10
BRPI0720991A2 (pt) 2014-03-18
AU2007342028B2 (en) 2013-06-13
WO2008083288A2 (en) 2008-07-10
WO2008083288A3 (en) 2008-10-02
MX2009006969A (es) 2010-04-07
AU2007342028A1 (en) 2008-07-10
CN107090482A (zh) 2017-08-25
CN101801994A (zh) 2010-08-11
EP2102230A2 (en) 2009-09-23
US8691534B2 (en) 2014-04-08
US20090209616A1 (en) 2009-08-20
US20090186382A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
BRPI0720991A8 (pt) Preparação da romidepsina
AR064456A1 (es) Anticuerpos cd 44
EP2124990A4 (en) TUMOR TREATMENT BASED ON ROMIDEPSIN
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
MX344973B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina.
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
BR112014015909A8 (pt) composição
BRPI0812609A2 (pt) método para separar pelo menos um componente de uma composição que compreenda pelo menos dois derivados de óleos de sementes
BRPI0519496A2 (pt) processo para preparar um composto ou uma composiÇço, e, composiÇço
ECSP088854A (es) Moduladores bencimidazolicos de vr1
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
CY1110943T1 (el) Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης
PY09010618A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
TW200745003A (en) Novel compounds
AR050717A1 (es) Composiciones farmaceuticas
BRPI0508610A (pt) derivados de aminoácidos
BR112014016412A2 (pt) método e sistema para a produção de água produzida
BRPI0418474A (pt) solução aquosa parenteral estável
BR112013031146A2 (pt) liberação direcionada de compostos retinóides para as glândulas sebáceas
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SANDOZ GMBH (AT) , CELGENE CORPORATION (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.